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OBJECTIVES: To describe the prevalence of the reduced ankle-brachial index (ABI) in patients with heart failure
(HF) with preserved ejection fraction (HFpEF) attended at a HF clinic in the metropolitan region of Porto Alegre,
and to compar the patients to those with reduced ejection fraction (HFrEF).
METHODS: A descriptive observational study, included patients referred to the heart failure clinic in HU-Ulbra
with HFpEF or HFrEF and diastolic dysfunction, and measurements of ABIs using vascular Doppler equipment
were performed in both groups.
RESULTS: The sample consisted of 106 patients with HF, 53.9% of the patients had HFpEF, and 19.4% had a
diagnosis of peripheral arterial disease (PAD) (ABI less than 0.9). PAD was identified in 24.1% of the patients
with HFpEF, while15.8% of patients in the HFrEF group were diagnosed with PAD.
CONCLUSION: Our results did not identify a significantly different prevalence of altered and compatible PAD
values in patients with HFpEF. However, we showed a prevalence of 19.4%, a high value if we consider similar
populations.
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’ INTRODUCTION
Heart failure (HF) is a prevalent clinical syndrome in the
world population, and approximately two-thirds of cases
present coronary artery disease (CAD) as the main etiology
(1), with more than 50% of cases in North and Europe and
30% to 40% in Asia, Latin America and the Caribbean (2); HF
is associated with a more reserved prognosis after acute
myocardial infarction (AMI) (3).
Peripheral arterial disease (PAD) is also associated with
high mortality rates and cardiovascular events and affects
approximately 200 million people worldwide (4). Both HF
and PAD present common risk factors, such as diabetes
mellitus, systemic arterial hypertension (SAH), obesity,
increased age, smoking, inflammation, and atherosclerosis
(5). This condition increases the cardiovascular risk for the
onset of HF and is an independent factor of hospitalization
and mortality (6).
Measurement of the ankle-brachial index (ABI) has already
been established in clinical practice for the diagnosis of
PAD (7-9). Studies correlate a low ABI (p0.9) with a higher
incidence of cerebrovascular diseases, specifically in patients
with HF (7). However, PAD is underdiagnosed and/or
undertreated, which makes it a complication factor (3,10).
Considering this rationale, the present study aims to des-
cribe the prevalence of PAD, with a diagnosis made through
ABI measurement, in patients with HF with preserved
ejection fraction (HFpEF) attended at a HF clinic of a non-
transplant hospital in the metropolitan region of Porto
Alegre.
’ METHODS
The study population was composed of adult patients over
18 years of age who were followed up at the Heart Failure
Outpatient Clinic of the University Hospital (HU) of the
Lutheran University of Brazil and were consecutively refer-
red for diagnosis of HF according to the Boston criteria from
the general cardiology outpatient clinic of the same institu-
tion. Patients with musculoskeletal alterations or ulcers
in the lower limbs that obstructed access to the brachial,
posterior tibial or pedal arteries and consequently, the
measurement of ABI or those who refused to participate in
the study were excluded.
The data were collected according to a protocol approved
by the research ethics committee - CEP of the ULBRA (358/
2010), and all the patients who fulfilled the inclusion criteria
signed a free and informed consent form, according to the
annex. The collection of data and records was carried
out by volunteer researchers responsible for the referral ofDOI: 10.6061/clinics/2019/e978
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the patients to the HU heart failure outpatient clinic.
Demographic, clinical, echocardiographic, and ABI values
were recorded. The diagnosis of HFpEF followed the cur-
rent European Society of Cardiology criteria (11), which
include HF signs and symptoms associated with diastolic
dysfunction criteria and LV ejection fraction greater than
or equal to 50%, both defined by transthoracic echocardio-
graphy (11).
The ABI measurement was performed by two previously
trained researchers using vascular Doppler equipment
(MARTEC, model DV-600, São Paulo, Brazil) and an aneroid
sphygmomanometer (Premium) duly calibrated for the esti-
mation of systolic pressure of the ankle, using the posterior
or pediatric tibial pulse and brachial systolic pressure and
using the right and left brachial pulse. The technique to
perform ABI was based on the guidelines of the European
Society of Cardiology (12) and was used to determine the
ratio between the higher ankle/pedal blood pressure (SBP)
and the respective systolic brachial pressure (SBP) measured
on both sides. The range of normality is between 1.00 - 1.39,
with values of 0.91 to 0.99 considered the lower limit and
1.3 to 1.4 the upper limit. Values less than or equal to 0.9 were
considered criteria for the diagnosis of PAD; those above 1.4
are related to arterial stiffening (12).
Statistical Analysis and Data Processing
The frequency data are presented as the means, standard
deviations and percentages. Continuous variables are pre-
sented as the means and standard deviation and compared
using a paired Student’s t-test for independent samples in
the comparison between groups. Categorical variables are
expressed as percentages and compared by the Chi-square
test. P values less than 0.05 were considered indicative of
significance. Statistical analysis was performed using IBM
SPSS software version 23.0 (Statistical Package for Social
Sciences, USA)
’ RESULTS
A total of 112 patients were included, and it was possible
to measure ABI in 106 of them; 6 were excluded because of
one of the exclusion criteria: one due to the presence of
venous ulcers, two due to refusal to perform the measure-
ments and amputation of the lower limb, and two because of
incalculable measures of ITB due to advanced disease.
The mean age was 65.7±11.8 years, the mean BMI was
29.3 kg/m2, and 53.4% of the participants were female. Class
II of the New York Heart Association functional classification
prevailed in our sample (Table 1).
The prevalence of ischemic heart disease as a basic
pathophysiology in the development of HF was 68% (Table 1).
The population presented a prevalence of 53.9% of the
diagnosis of HFpEF (Table 1). The prevalence of ABI in the
general population compatible with a diagnosis of PAD was
19.4% and was not significantly different between patients
with HFpEF and heart failure with reduced ejection fraction
(HFrEF) (24.1% versus 15.8%, p=0.442), respectively. The pre-
valence of smoking was higher in the HFpEF group (Table 2).
’ DISCUSSION
The population in the present study shows a high
prevalence of patients with HFpEF. This observation may
be related to the bias of the institution to have an IC clinic
dedicated to the assistance and research of this clinical syn-
drome. In this context, the general characteristics of our
HFpEF sample are similar to those described in most publi-
cations, and our sample has a higher proportion of women
and more advanced age, as is the case with current registries
(13). In addition, we observed in our population that
smoking, a factor typically associated with atherosclerosis
and PAD, was significantly higher in patients with HFpEF.
The prevalence of the diagnosis of PAD by ABI in the
general population was high (19.4%), but the difference was
not statistically significant when the population was dichot-
omized by the ejection fraction of the left ventricle in the
HFpEF and HFrEF (24.1%x15.8%, p=NS). Several factors may
explain this phenomenon, including atherosclerotic load and
the distribution of ischemic heart disease rates (14).
In two meta-analyses, Hajibandeh S, et al. (15) and Hao Z,
et al. (16) assessed a high risk of CAD (outcomes composed
of AMI) in patients with reduced ITB. Likewise, a study by
Hisayama (17) found a 4.11-fold risk of CAD in patients with
reduced ABI without previous CVD. Moussa I, et al. (18)
observed a PAD prevalence of 15% in patients diagnosed
with CAD, a rate that was also similar to our data. However,
in our data, similar rates of CAD were registered in the
groups with HFrEF and HFpEF (55.6%x44.4%, p=NS), which
Table 1 - Clinical Characteristics of Patients with ICFER and ICFEP.
N=106 patients
Variables Values
Anthropometric Data
Age (years) 65.75±11.88
BMI (kg/m2) 29.38±7.14
Female (%) 53. 4
CFNYA I (%) 30.3
CFNYA II (%) 44.8
CFNYA III (%) 20
CFNYA IV (%) 3.6
Comorbidities (%)
Arterial hypertension 83.2
Diabetes mellitus 39.5
Dyslipidemia 54.7
AMI 30.5
Arrhythmia 16.8
FHSD 13.7
Smokers (%) 14
Ex-smokers (%) 47
Nonsmokers (%) 39
Medications (%)
Beta Blocker 74.7
ACE 41.6
ARB 40.3
BCC 35.2
Furosemide 52.1
Thiazide 31.6
Spironolactone 52.1
Variables ABI and ECO
ABI changed (%) 19.4
ABI minor 0.79±0.16
ABI greater 1.11±0.12
LVEFr (%) 46.1
LVEFp (%) 53.9
BMI: body mass index; CFNY: functional class of the New York Heart
Association; ACE inhibitors: angiotensin converting inhibitor; ARB:
angiotensin receptor blocker; BCC: calcium channel blockers; AMI: acute
myocardial infarction; FHSD: family history of sudden death; ABI: ankle-
brachial index; LVEFr: left ventricular ejection fraction reduced; LVEFp: left
ventricular ejection fraction preserved.
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may have balanced the atherosclerotic loads and the chances
of ABI indicative of PAD.
Evaluating the phenomenon from another perspective,
Khaira KB, et al. (19) investigated the prevalence of HF in
patients with PAD at more advanced stages. Of the 381
patients in their study, 31% had a previous history of HF, and
the majority of the patients (62%) had HFpEF. At the same
time, we had a high rate of HFpEF (53.9%), and the affected
individuals had a high rate of PAD (24.1%). As already
demonstrated in the MAGGIC study (20), this result suggests
that the profile of patients with HFpEF, with more advanced
age and a higher number of comorbidities, would facilitate a
presentation of a more chronic, slower-growing and mature
atherosclerosis load related to the peripheral arterial vessel.
This association of HFpEF and PAD can still be considered a
plausible hypothesis to explain the peripheral component of
heart failure in this population, that is, muscle insufficiency
in response to an increase in demand could be explained, at
least in part, by arterial insufficiency in approximately one-
quarter of our patients (20).
A risk factor for atherosclerotic disease that was signifi-
cantly different between the two HF groups was smoking,
being more prevalent in the HFpEF population (26%x16%,
p=0.001). This factor is cited as associated with the risk of
PAD in several studies and may have contributed to the high
rates of diagnosis of PAD in both populations, although
mainly in patients with HFpEF (21,22).
However, when we compare our results with other studies
of populations with HF, we are surprised by our rates of
PAD. A post hoc analysis of 2331 subjects included in the
randomized controlled trial (HF-ACTION) (23) testing phy-
sical training for HF patients found a PAD rate of 6.8%.
Likewise, another study analyzing 28,771 patients with LV
dysfunction or HF after AMI, combined in a meta-analysis of
four randomized trials, observed a prevalence of only 8.2%
of PAD (6). In both studies, the prevalence of PAD was much
lower than ours, leading to the hypothesis that our popu-
lation is actually more severe or that the disease criteria used
are more sensitive than the cited publications.
Our results corroborate the current recommendations for
the European Society of Cardiology and European Society of
Vascular Surgery (12), which emphasize the importance of
establishing this diagnosis due to the independent predictive
power for hospitalization and all-cause mortality in patients
with HF (4,6,9,15,16,24) and a risk factor for cardiovascular
events, except stroke, in those without a previous history of
HF (6,19).
Limitations
Our study has limitations regarding the number of parti-
cipants involved, because we analyzed all patients with data
available in our database and may demonstrate data that are
more consistent with the natural increase in the study sample
in the future. In addition, the potential for ITB calibra-
tion bias should always be considered due to its inter- and
intraobserver variability.
’ CONCLUSION
Our results identified a high prevalence of PAD diagnosed
by arterial Doppler-mediated ABI in patients diagnosed
with HFpEF; however, there was no statistically significant
difference in these rates compared to patients with HFrEF.
These results point to a trend and deserve to be further
investigated in the future.
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